enCore Energy Corp. Announces Option Grants to Officers
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- enCore Energy Corp. (TSXV: EU; OTCQX: ENCUF) (the “Company”) announces that it has granted incentive stock options (the “Options”) to certain of its officers and consultants, to purchase an aggregate of up to 435,000 common shares in the capital of the Company at a price of $ 1.08 per share for a five year period, in accordance with its Stock Option Plan. Vesting will occur over a period of eighteen months, with an initial 25% of the Options vesting immediately upon grant, followed by an additional 25% of the Options every six months thereafter until fully vested.
For further information please contact the undersigned.
About enCore Energy Corp.enCore Energy Corp. is a U.S. domestic uranium developer focused on becoming a leading in-situ recovery (ISR) uranium producer. The Company is led by a team of industry experts with extensive knowledge and experience in the development and operations of in situ recovery uranium operations. enCore Energy’s opportunities are created from the Company’s transformational acquisition of its two South Texas production facilities, the changing global uranium supply/demand outlook and opportunities for industry consolidation. These short-term opportunities are augmented by our strong long term commitment to working with local indigenous communities in New Mexico where the company holds significant uranium resources.
For additional information:William M. SheriffExecutive Chairman972-333-2214info@encoreenergycorp.com www.encoreenergycorp.com
Source: enCore Energy Corp.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
- Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
- New Clinical Responses for AGEN1181 Presented at AACR
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!